AI brings its own validation challenges. Unlike static assays, machine learning algorithms evolve as they ingest new data, ...

Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in ...

This story was produced in partnership with Teen Vogue and reprinted with permission. This story also appeared in Teen Vogue Christopher Cade wants to be president someday. His inspiration largely ...

Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in ...

THE Movement for a Livable Cebu (MLC) is calling for six immediate actions from the government to address what it described as Cebu’s worsening flood crisis. Th ...

Q3 2025 Earnings Call Transcript November 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07. Operator: Greetings, and welcome to the Vaxart Business ...

Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 HNSCC registrational study planned to start ...

After a remarkable recovery from a very deep crisis in 2022, Sri Lanka’s recent Budget consolidates economic stablisation and ...

The future of Moe's Valley, a popular climbing and biking area, has become entangled with the polarizing Northern Corridor.

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

THE Philippine government should consider opening up mass media to foreign ownership to help traditional media overcome financial challenges, according to a senior researcher of local think tank ...

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment in CHAPTER-3, a pivotal Phase 3 ...